RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID
Trial status:Study Complete
Study Identifier:
BN_0002-01
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Study Complete
Trial details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female
Age
18+
Estimated Trial Date
Oct 2016 - May 2020
Protocol summary
The Mutanome Engineered RNA Immuno-Therapy (MERIT) study introduces a novel concept for Individualized Cancer Immunotherapy (IVAC®) to treat each patient with the relevant and immunogenic RNA vaccines for a given patient's tumor. The TNBC-MERIT trial uses two complementary strategies, the WAREHOUSE and the IVAC® MUTANOME concept, resulting in two custom-made IVAC® investigational medicinal products (IMPs) (IVAC_W_bre1_uID and IVAC_M_uID) for each individual patient.
Trial locations
Location
Status
Location
Johannes Gutenberg University
Mainz, RLP, Germany, 55131
Status
Location
National Center for Tumor Diseases (NCT)
Heidelberg, Germany, 69120
Status
Location
Dr. Horst Schmidt-Kliniken Wiesbaden
Wiesbaden, Germany, 65199
Status
Location
Uppsala University Hospital
Uppsala, Sweden, 75185
Status